Coloplast A/S (CLPBY) Expected to Announce Quarterly Earnings on Tuesday

Coloplast A/S (OTCMKTS:CLPBY) will likely be issuing its quarterly earnings data on Tuesday, February 4th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Coloplast A/S has set its FY 2025 guidance at EPS.

Coloplast A/S (OTCMKTS:CLPBY) last issued its earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. The company had revenue of $1.02 billion during the quarter. On average, analysts expect Coloplast A/S to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Coloplast A/S Trading Up 2.0 %

OTCMKTS CLPBY opened at $11.66 on Tuesday. The business’s fifty day simple moving average is $11.58 and its 200-day simple moving average is $12.62. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92. Coloplast A/S has a 52 week low of $10.63 and a 52 week high of $14.34.

Coloplast A/S Increases Dividend

The company also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were paid a dividend of $0.2435 per share. The ex-dividend date was Monday, December 9th. This is an increase from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s payout ratio is 93.94%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CLPBY. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.